This September, leaders in nanotechnology will gather in Vancouver, British Columbia, to share the latest ideas for developing nanomedicines for various diseases.

The three days of idea sharing will begin with the Vancouver Nanomedicine Day 2019 on September 12th that include talks by Dr. Christine Allen (University of Toronto), Dr. Pieter Cullis (The University of British Columbia), Dr. Tayyaba Hasan (Harvard Medical School), and Dr. Shana Kelley (University of Toronto). The event is free and researchers are invited to submit an abstract (deadline is August 12, 2019).

On September 13th and 14th, the two-day NMIN Scientific Meeting will include world-renowned nanotech researchers to share their latest data and ideas. Among the speakers will be Dr. Marcel Bally (University of British Columbia), Dr. Pieter Cullis (University of British Columbia), Dr. Christian Kastrup,  Dr. Shana Kelley (University of Toronto), Dr. Shyh-Dar Li (University of British Columbia), Diana Royce (NMIN), and Dr. Gilbert Walker (University of Toronto).

The two-day event will also include presentations by key industry partners who will share their priorities and perspectives on nanomedicine’ past, present, and future.

Nanomedicine research employs medical technologies at the nanoscale, ranging from drug delivery carriers and imaging agents to nanomaterials and nanoelectronic biosensors.

Nanomedicine technology could revolutionize the way medicines get developed and leading that charge is the Nanomedicines Innovation Network (NMIN), a group of researchers across Canada was recently awarded over $18 million by the Government of Canada to develop and monetize various nanotechnologies for targeted therapies, gene therapies, and diagnostic tools.

And they hope their research will lead to new companies that can stimulate the economy. To date, the NMIN researchers have already been instrumental in developing six approved nanomedicines, including Jazz Therapeutics’ Vyxeos to treat acute myeloid leukemia and Alnylam’s Onpattro to treat ATTR amyloidosis, and they hope this new initiative will generate billions for the Canadian economy while also developing more effective ways to treat and diagnosis many conditions, including many rare genetic conditions.

For more information, visit